Incyte Genomics, Inc. (INCY) Posts Narrower than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $124.82 +0.14%
Revenue Growth %: +7.3%
Financial Fact:
Diluted (in dollars per share): 0.19
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +7.3%
Financial Fact:
Diluted (in dollars per share): 0.19
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q3 loss of ($0.42), $0.03 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.54 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte to present skin disease data at EADV congress in Vienna
- Children's Place (PLCE) Misses Q2 EPS by 20c
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
